EDC3 Knockout Jurkat Polyclonal Cells provide a loss-of-function model generated by CRISPR/Cas9-mediated gene disruption of the EDC3 locus within a Jurkat T lymphocyte background. This polyclonal population carries heterogeneous gene edits, offering a robust tool for investigating the functional role of EDC3 in mRNA decapping and post-transcriptional gene regulation without the selection pressure of clonal expansion. The cells enable detailed dissection of decapping complex dynamics and mRNA turnover pathways in a physiologically relevant immortalized T cell model.
Jurkat cells are a human T lymphoblastoid line originally derived from the peripheral blood of a 14-year-old boy with acute lymphoblastic leukemia. These cells are widely employed as a model system for T cell receptor signaling, apoptosis, and leukemogenesis due to their rapid proliferation and well-characterized signaling cascades. Their leukemic origin provides a context for examining mRNA metabolic processes linked to hematological malignancies, making them particularly suitable for assessing how dysregulation of mRNA stability contributes to cancer biology.
EDC3 encodes an enhancer of mRNA decapping, acting as a scaffold protein that directly stimulates the catalytic activity of the DCP2 decapping enzyme. It localizes to cytoplasmic processing bodies (P-bodies) where it forms complexes with DCP1A, DDX6, PatL1, and the LSm1-7 complex, facilitating recruitment of the 5′-to-3′ exoribonuclease XRN1. EDC3 activity is regulated by upstream RNA-binding proteins such as TTP and HuR, as well as stress-responsive signaling pathways including p38 MAPK and mTOR. Through these interactions, EDC3 promotes the removal of the 5′ cap and subsequent degradation of target mRNAs, thereby reducing their stability and dampening protein output.
In Jurkat cells, EDC3 knockout disrupts the normal decapping equilibrium, allowing researchers to evaluate how compromised mRNA surveillance impacts T cell homeostasis and leukemic phenotypes. The model is particularly valuable for exploring connections between post-transcriptional regulation and neurodevelopmental disorders, as EDC3 mutations have been linked to intellectual disability. By ablating EDC3 function in a leukemia-derived line, investigators can study convergent mechanisms of RNA metabolism that underlie both developmental and oncogenic processes, including altered P-body assembly and aberrant stabilization of mRNAs encoding oncoproteins or cytokines.
Researchers can employ these polyclonal knockout cells in a wide range of downstream assays, including actinomycin D chase experiments to measure mRNA half-life, luciferase decay reporters for real-time decapping kinetics, and quantitative RT-PCR to assess transcript-specific stabilization. Co-immunoprecipitation studies enable interrogation of residual decapping complex integrity, while immunofluorescence microscopy reveals P-body morphology and distribution. RNA sequencing combined with metabolic labeling (e.g., 4-thiouridine) allows transcriptome-wide analysis of mRNA turnover, and polysome profiling examines translation efficiency shifts. The polyclonal nature also supports pooled CRISPR screening applications. For further assistance with experimental design or ordering, please contact Ascent Research.
